Abbott Laboratories Draws Bullish Options Activity Today

 Abbott Laboratories Draws Bullish Options Activity Today

In today’s session Abbott Laboratories (ABT) registered an unusually high (5,619) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ABT increase. With 5,619 contracts traded and 120294 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ABT170120C00043000 closed last at: $0.28 or 17.6% down. About 408,953 shares traded hands. Abbott Laboratories (NYSE:ABT) has declined 7.02% since April 5, 2016 and is downtrending. It has underperformed by 8.97% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Out of 16 analysts covering Abbott Laboratories (NYSE:ABT), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. $90 is the highest target while $9 is the lowest. The $48.83 average target is 22.60% above today’s ($39.83) stock price. Abbott Laboratories has been the topic of 40 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Jefferies maintained the shares of ABT in a report on Thursday, July 14 with “Buy” rating. As per Monday, January 4, the company rating was downgraded by Morgan Stanley. The firm earned “Buy” rating on Saturday, August 29 by Deutsche Bank. The firm earned “Overweight” rating on Wednesday, October 7 by Barclays Capital. As per Tuesday, June 21, the company rating was upgraded by Edward Jones. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Tuesday, June 14. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, July 23. The firm has “Buy” rating given on Tuesday, March 15 by Jefferies. Goldman Sachs downgraded Abbott Laboratories (NYSE:ABT) rating on Friday, November 13. Goldman Sachs has “Neutral” rating and $90 price target. Jefferies maintained the shares of ABT in a report on Tuesday, September 13 with “Buy” rating.

According to Zacks Investment Research, “Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.”

Insitutional Activity: The institutional sentiment increased to 1.05 in 2016 Q2. Its up 0.18, from 0.87 in 2016Q1. The ratio improved, as 68 funds sold all Abbott Laboratories shares owned while 488 reduced positions. 79 funds bought stakes while 507 increased positions. They now own 1.05 billion shares or 2.91% more from 1.02 billion shares in 2016Q1.
New York State Teachers Retirement Systems has 0.29% invested in the company for 2.78 million shares. Glg reported 39,789 shares or 0.12% of all its holdings. Zwj Invest Counsel Incorporated holds 0.16% of its portfolio in Abbott Laboratories (NYSE:ABT) for 40,687 shares. Moreover, Boys Arnold And has 0.52% invested in Abbott Laboratories (NYSE:ABT) for 76,471 shares. Moreover, Argentus Capital Limited Liability Co has 0.08% invested in Abbott Laboratories (NYSE:ABT) for 4,823 shares. Moreover, Bremer Tru Association has 0.14% invested in Abbott Laboratories (NYSE:ABT) for 12,544 shares. Moreover, Folger Nolan Fleming Douglas Cap Mngmt has 0.69% invested in Abbott Laboratories (NYSE:ABT) for 102,434 shares. Vanguard Grp Inc last reported 0.24% of its portfolio in the stock. The France-based Bnp Paribas Inv Prns has invested 0.05% in Abbott Laboratories (NYSE:ABT). Moreover, Rnc Cap Management has 0.03% invested in Abbott Laboratories (NYSE:ABT) for 9,170 shares. Bbva Compass Bancshares holds 0.59% of its portfolio in Abbott Laboratories (NYSE:ABT) for 199,627 shares. Brandywine Tru accumulated 224,855 shares or 5.91% of the stock. Janney Cap Mgmt Ltd accumulated 5,177 shares or 0.01% of the stock. Outfitter Ltd last reported 0.09% of its portfolio in the stock. Bartlett And Ltd holds 1.62% or 833,051 shares in its portfolio.

Insider Transactions: Since June 1, 2016, the stock had 2 insider purchases, and 7 sales for $6.28 million net activity. 815 shares were sold by Salvadori Daniel Gesua Sive, worth $33,994. Blount Sally E. also bought $200,124 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, November 1. 3,400 Abbott Laboratories (NYSE:ABT) shares with value of $126,276 were sold by ALLEN HUBERT L. Fussell Stephen R also sold $1.87 million worth of Abbott Laboratories (NYSE:ABT) shares. On Tuesday, July 26 Warmuth Michael J sold $1.17M worth of the stock or 26,800 shares. WHITE MILES D also bought $10.47 million worth of Abbott Laboratories (NYSE:ABT) on Monday, July 25. The insider YOOR BRIAN B sold 565 shares worth $22,312.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The company has a market cap of $57.75 billion. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 59.91 P/E ratio. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

ABT Company Profile

Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Wsj.com which released: “Abbott Labs Swings to Loss After Booking Charge on Mylan Stake” on October 19, 2016, also Thestreet.com with their article: “Abbott Labs (ABT) Stock Up on Q3 Earnings Beat” published on October 19, 2016, Valuewalk.com published: “Morgan Stanley Beats Estimates, Abbott Laboratories Just Ahead” on October 19, 2016. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Reuters.com and their article: “Abbott offers EU concessions over $25 billion St. Jude deal” published on November 03, 2016 as well as Bna.com‘s news article titled: “Ex-Abbott Labs Sales Manager Gets $4.25M for Age Bias” with publication date: October 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment